Clinical trials: Patients With Diabetes.
Diabetes Mellitus, Type 2
Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes
Vildagliptin is an oral anti-diabetic agent. This is a 24-week study to assess the efficacy on HbA1c of 100 mg vildagliptin once daily as compared to placebo as add-on to metformin in patients with type 2 diabetes inadequately…
- Trial name
- NCT00351884
- Testing
- Vildagliptin AM, vildagliptin pm
- Where
- 2 sites in United States, Germany
- Volunteers
- 370 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Foot Ulcer
TWB-103 for Treating Lower Limb Ulcers on Patients With DM
Primary Objective: To assess the safety profile of TWB-103 administered to subjects with diabetic lower limb ulcers Secondary Objective: To explore the efficacy of TWB-103 administered to subjects with diabetic lower limb ulcers
- Trial name
- NCT03624023
- Testing
- TWB-103
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Transwell Biotech Co., Ltd.
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated haemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 diabetes mellitus (T1DM) also using insulin glargine.
- Trial name
- SORELLA1 (NCT02273180)
- Testing
- SAR342434, Humalog, Insulin glargine HOE901
- Where
- 89 sites in United States, France and 6 more
- Volunteers
- 507 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
The trial is conducted in Asia. The aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in Taiwanese patients with type 2 diabetes failing on OAD with/without once-daily NPH Insulin treatment.
- Trial name
- NCT00521690
- Testing
- insulin detemir
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Hypomagnesemia in Type 2 Diabetic Patients
MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10 mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.
- Trial name
- NCT03567824
- Testing
- Magnesium L-lactate dihydrate
- Volunteers
- 200 people
- Sponsor
- Pharmalyte Solutions LLC
Type 2 Diabetes
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
- Trial name
- NCT01455883
- Testing
- ITCA 650 60 mcg/day, glimepiride
- Where
- United States
- Sponsor
- Intarcia Therapeutics
Type 2 Diabetes
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
Exenatide twice daily has been studied in Japanese type 2 diabetes patients. A once-weekly version of exenatide is currently being evaluated. Study GWBW is the first study of exenatide once weekly in Japanese patients.
- Trial name
- NCT00612794
- Testing
- exenatide once weekly
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.
- Trial name
- NCT01224366
- Testing
- Vildagliptin
- Where
- 66 sites in Australia, Belgium and 9 more
- Volunteers
- 448 people
- Sponsor
- Novartis
Diabetic Nephropathy
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout.
- Trial name
- UPWARD (NCT02327754)
- Testing
- Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Type 1 Diabetes
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Primary objective To determine whether oral ladarixin versus placebo adjunctive therapy improves glycemic control in overweight, insulin resistant (IR) adult subjects with type 1 diabetes (T1D).
- Trial name
- CONSERVA (NCT05368402)
- Testing
- Ladarixin
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Dompé Farmaceutici S.p.A
T2DM (Type 2 Diabetes Mellitus)
Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
- Trial name
- NCT04014023
- Testing
- DWP16001
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Pain, Diabetic Neuropathy
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
- Trial name
- NCT00857623
- Testing
- AZD2066
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Type 2 Diabetes Mellitus
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.
- Trial name
- CWP-DIANA-302 (NCT01529541)
- Testing
- Anagliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes
Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
The study objectives are to assess over the gliclazide MR-SGLT2i combined treatment course in patients with T2DM adding SGLT2i to gliclazide MR-based therapy.
- Trial name
- ADD2DIA (NCT06708091)
- Where
- France
- Volunteers
- 537 people
- Sponsor
- Servier Affaires Médicales
Diabetes Mellitus Type 2
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00111670
- Testing
- DPP-IV Inhibitor
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
Ranibizumab "Treat and Extend" in Diabetic Macular Edma
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to…
- Trial name
- OPTIMAL (NCT01297569)
- Testing
- Ranibizumab
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
Amidst medical innovations, many Type 1 diabetes patients using advanced therapy show improved control but still suffer from diabetes-related distress.
- Trial name
- PRO-DIAB-1 (NCT06050642)
- Testing
- enhanced care model provided by Timkl, a home support provider
- Where
- France
- Volunteers
- 340 people
- Sponsor
- timkl
T2DM
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
After a screening, a 2-week, single-blind placebo run-in, 174 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Gemigliptin 50 mg or placebo to ongoing stable doses of glimepiride in combination…
- Trial name
- NCT01990469
- Testing
- Gemigliptin
- Volunteers
- 219 people
- Sponsor
- LG Life Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.